Cytek Biosciences (CTKB) Net Margin (2020 - 2026)
Cytek Biosciences (CTKB) posted Net Margin of 42.75% for Q1 2026, up 39.73% on a QoQ basis from 70.93% in Q4 2025, and down 1524.0% year-over-year from 3.0% in Q1 2025.
Cytek Biosciences (CTKB) Net Margin (2020 - 2026) Analysis & Trends
Cytek Biosciences' Net Margin history runs 7 years deep, the most recent figure standing at 42.75% for Q1 2026.
- Quarterly Net Margin fell 1524.0% year-over-year to 42.75% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 36.25% (down 3054.0% YoY) and the FY2025 annual result came in at 33.02%, down 3002.0% from the prior year.
- Net Margin was 42.75% for Q1 2026 at Cytek Biosciences, up from 70.93% in the prior quarter.
- Across five years, Net Margin topped out at 16.78% in Q4 2024 and bottomed at 70.93% in Q4 2025.
- A 5-year average of 12.26% and a median of 10.48% in 2025 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2024 — Net Margin jumped 1528 bps — and 2025, when it plunged 8771 bps.
- Cytek Biosciences' Net Margin stood at 7.3% in 2022, then climbed by 29 bps to 9.45% in 2023, then jumped by 78 bps to 16.78% in 2024, then tumbled by 523 bps to 70.93% in 2025, then soared by 40 bps to 42.75% in 2026.
- Business Quant data shows CTKB's Net Margin at 42.75% in Q1 2026, 70.93% in Q4 2025, and 10.48% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 9.65% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 12.38% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 12.84% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 25.77% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | - |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 16.74% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 3.87% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 8.01% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Cytek Biosciences | 586.89 Mn | 521.19 Mn | 21.25 Mn | -42.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42.75% |
| Dec 31, 2025 | -70.93% |
| Sep 30, 2025 | -10.48% |
| Jun 30, 2025 | -12.24% |
| Mar 31, 2025 | -27.50% |
| Dec 31, 2024 | 16.78% |
| Sep 30, 2024 | 1.83% |
| Jun 30, 2024 | -22.38% |
| Mar 31, 2024 | -13.75% |
| Dec 31, 2023 | 9.45% |
| Sep 30, 2023 | -13.45% |
| Jun 30, 2023 | -8.83% |
| Mar 31, 2023 | -18.35% |
| Dec 31, 2022 | 7.30% |
| Sep 30, 2022 | 4.12% |
| Jun 30, 2022 | -1.49% |
| Mar 31, 2022 | -5.76% |
| Sep 30, 2021 | 1.01% |
| Mar 31, 2021 | 0.42% |
| Dec 31, 2020 | 1.88% |